MX2022016533A - Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos. - Google Patents

Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos.

Info

Publication number
MX2022016533A
MX2022016533A MX2022016533A MX2022016533A MX2022016533A MX 2022016533 A MX2022016533 A MX 2022016533A MX 2022016533 A MX2022016533 A MX 2022016533A MX 2022016533 A MX2022016533 A MX 2022016533A MX 2022016533 A MX2022016533 A MX 2022016533A
Authority
MX
Mexico
Prior art keywords
psychoactive
organisms
compounds
compositions
extraction
Prior art date
Application number
MX2022016533A
Other languages
English (en)
Inventor
Benjamin Lightburn
Ryan Moss
Lisa Ranken
Original Assignee
Psilo Scient Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3088384A external-priority patent/CA3088384C/en
Priority claimed from CA3097246A external-priority patent/CA3097246C/en
Priority claimed from CA3101765A external-priority patent/CA3101765A1/en
Priority claimed from CA3103707A external-priority patent/CA3103707C/en
Application filed by Psilo Scient Ltd filed Critical Psilo Scient Ltd
Priority claimed from PCT/CA2021/050813 external-priority patent/WO2021253116A1/en
Publication of MX2022016533A publication Critical patent/MX2022016533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0215—Solid material in other stationary receptacles
    • B01D11/0253—Fluidised bed of solid materials
    • B01D11/0257—Fluidised bed of solid materials using mixing mechanisms, e.g. stirrers, jets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/028—Flow sheets
    • B01D11/0284—Multistage extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0292—Treatment of the solvent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se relaciona con la extracción de compuestos psicoactivos de organismos para su uso en medicina. La extracción se lleva a cabo con un ácido fuerte o una base fuerte para promover o inhibir la desfosforilación. El extracto en forma de suspensión se estandariza con un excipiente agregado de modo que cuando se seca, la composición en polvo tiene una concentración específica de alcaloides psicoactivos totales, con una proporción conocida de alcaloides psicoactivos fosforilados a desfosforilados.
MX2022016533A 2020-06-17 2021-06-14 Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos. MX2022016533A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063040317P 2020-06-17 2020-06-17
US202063046089P 2020-06-30 2020-06-30
CA3088384A CA3088384C (en) 2020-06-17 2020-07-29 Extraction of psychoactive compounds from psilocybin fungus
CA3089455A CA3089455C (en) 2020-06-17 2020-08-07 Methanol-based extraction of psychoactive compounds from fungus
CA3097246A CA3097246C (en) 2020-10-23 2020-10-23 Process for obtaining a purified psychoactive alkaloid solution
CA3101765A CA3101765A1 (en) 2020-12-04 2020-12-04 Psychoactive alkaloid extraction and composition with controlled dephosphorylation
CA3103707A CA3103707C (en) 2020-12-18 2020-12-18 Standardized psychoactive alkaloid extract composition
PCT/CA2021/050813 WO2021253116A1 (en) 2020-06-17 2021-06-14 Compositions comprising psychoactive compounds from psychoactive organisms

Publications (1)

Publication Number Publication Date
MX2022016533A true MX2022016533A (es) 2023-04-05

Family

ID=79022851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016533A MX2022016533A (es) 2020-06-17 2021-06-14 Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos.

Country Status (6)

Country Link
US (4) US11331357B2 (es)
EP (1) EP4161546A1 (es)
AU (7) AU2021290454B2 (es)
BR (1) BR112022025780A2 (es)
IL (9) IL299452A (es)
MX (1) MX2022016533A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス， インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
CA3197443A1 (en) 2020-12-28 2022-06-28 Psilo Scientific Ltd. Processes for extracting psychoactive alkaloids and preparation thereof into transmucosal forms
WO2023225186A1 (en) * 2022-05-18 2023-11-23 Chemtor, Lp Extraction of psilocybin and psilocin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE264023C (es)
GB911946A (en) 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
LU36879A1 (es) 1958-02-21
DD264023A1 (de) * 1987-07-17 1989-01-18 Akad Wissenschaften Ddr Verfahren zur extraktion von indolalkaloiden aus pilzmaterial
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
MXPA04008213A (es) 2002-02-28 2005-05-16 Mallinckrodt Inc Metodo y sistema para la separacion y purificacion de por lo menos un alcaloide narcotico usando cromatografia preparativa de fase inversa.
SE0302947D0 (sv) 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
ES2536922T3 (es) 2006-09-15 2015-05-29 Echo Pharmaceuticals B.V. Unidad de dosificación para administración sublingual, bucal u oral de sustancias farmacéuticamente activas insolubles en agua
CN101292727A (zh) 2008-05-30 2008-10-29 曹晋忠 菌类乙醇提取物的粉体制备方法
BR112012024835A2 (pt) 2010-03-30 2016-06-07 Phosphagenics Ltd adesivo de distribuição transdérmica
EP3160565B1 (en) 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20190142851A1 (en) * 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN114025750A (zh) 2019-03-07 2022-02-08 阿伯门蒂斯有限责任公司 包含神经可塑性作用物质的以非迷幻/致幻觉剂量和制剂给药的组合物和使用方法
JP2022529662A (ja) 2019-04-26 2022-06-23 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二重グリカン結合ａａｖ２．５ベクターのための方法および組成物
CA3097246C (en) 2020-10-23 2023-03-28 Psilo Scientific Ltd. Process for obtaining a purified psychoactive alkaloid solution
US20220304980A1 (en) 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
WO2021007152A1 (en) 2019-07-09 2021-01-14 Refraction Ai, Inc. Method and system for autonomous vehicle control
CA3124367C (en) 2020-06-17 2022-04-26 Psilo Scientific Ltd. Aqueous extraction of psychoactive compounds from psilocybin fungus
US11382942B2 (en) 2020-06-17 2022-07-12 Psilo Scientific Ltd. Extraction of psychoactive compounds from psilocybin fungus
US20220054402A1 (en) 2020-11-05 2022-02-24 Richard C Kaufman Compositions and methods for extracting, stabilizing, and manufacturing stable dosage forms of psilocin, psychedelic drugs, entheogens, and medicinal mushrooms as nano-dimensional drug delivery structures
US20220331292A1 (en) 2021-04-16 2022-10-20 Callitas Health Inc. Compositions and methods for delivery of psilocin and prodrugs thereof
US20220409584A1 (en) 2021-06-16 2022-12-29 Intelgenx Corp. Stable tryptamine oral films

Also Published As

Publication number Publication date
IL299452A (en) 2023-02-01
US11642385B2 (en) 2023-05-09
AU2022291410B2 (en) 2024-04-04
AU2022291413B2 (en) 2024-02-22
AU2022291411A1 (en) 2023-02-02
US11571450B2 (en) 2023-02-07
AU2022291414A1 (en) 2023-02-02
AU2022291410A1 (en) 2023-02-02
AU2022291413A1 (en) 2023-02-02
US11331357B2 (en) 2022-05-17
AU2022291411B2 (en) 2023-12-07
US20220040246A1 (en) 2022-02-10
IL299450A (en) 2023-02-01
BR112022025780A2 (pt) 2023-01-10
US20220226405A1 (en) 2022-07-21
IL305632A (en) 2023-11-01
IL299448A (en) 2023-02-01
AU2021290454A1 (en) 2023-01-19
IL297791A (en) 2022-12-01
AU2022291416A1 (en) 2023-02-02
IL299451A (en) 2023-02-01
EP4161546A1 (en) 2023-04-12
US20210393716A1 (en) 2021-12-23
AU2022291414B2 (en) 2023-12-07
IL299449A (en) 2023-02-01
AU2022291416B2 (en) 2024-03-28
IL298561A (en) 2023-01-01
US20220202886A1 (en) 2022-06-30
US11298388B2 (en) 2022-04-12
AU2023285751A1 (en) 2024-01-18
AU2021290454B2 (en) 2024-01-11
IL299453A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2022016533A (es) Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos.
PH12021550995A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
MX2022016531A (es) Extraccion de compuestos psicoactivos del hongo psicodelico.
PH12020551278A1 (en) N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
TN2012000265A1 (en) Triazolopyridines
MX2013002713A (es) Imidazopiridazinas sustituidas.
BRPI0610876A2 (pt) composto, mÉtodos de inibir uma atividade de uma jak cinase, de tratar uma doenÇa autoimune mediada por cÉlula t, de tratar ou prevenir rejeiÇço ao transplante de aloenxerto em um receptor de transplante, de inibir uma cascata de transduÇço de sinal que jak3 cinase desempenha um papel e de tratar ou prevenir uma doenÇa mediada por jak cinase, formulaÇço farmacÊutica, e, kit
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
PH12014501319A1 (en) Substituted triazolopyridines and their use as ttk inhibitors
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
EA201300288A1 (ru) Имидазо[4,5-c]хинолины в качестве ингибиторов днк-пк
MA46608B1 (fr) Formulation liposomale utile pour le traitement du cancer
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
MX2009003926A (es) Composiciones de fenilalquilamino-carbamato.
BR112018069530A2 (pt) composições de forma de dosagem que compreendem um inibidor da tirosina quinase de bruton
CR20220068A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
TN2014000433A1 (en) Dosage regimen for a pi-3 kinase inhibitor
EA202090448A1 (ru) Дигидрооксадиазиноны
SG10201907291QA (en) Monomethylfumarate prodrug compositions
PH12018500796A1 (en) Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide
MX2019015005A (es) Proceso para la preparación de composición estandarizada de arjunglucósido de la corteza de terminalia arjuna.
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
BR112019004486A2 (pt) compostos de 8-(azetidin-1-il)-[1,2,4] triazolo [1,5a] piridinil, composições e métodos de uso dos mesmos
MX341492B (es) Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona.
MX2023000577A (es) Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.